FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma
FLT3LG could be considered as a diagnostic and prognostic marker for LUAD and might play a role in enhancing the therapeutic response to immunotherapy in patients with LUAD.
Authors
- Hao Cheng (ORCID: https://orcid.org/0000-0002-5368-3613)
- Fengyi Zhao (ORCID: https://orcid.org/0000-0002-6360-6144)
- Shuoze Gao
- Jiao Ma (ORCID: https://orcid.org/0000-0003-3409-6349)
- Xinhan Zhao (ORCID: https://orcid.org/0009-0009-4344-3315)
- Shanzhi Gu (ORCID: https://orcid.org/0000-0001-6099-4543)
- Sida Qin (ORCID: https://orcid.org/0009-0003-0454-0493)
- Yiwei Liu (ORCID: https://orcid.org/0000-0001-9885-6429)
- Yuanyuan Li (ORCID: https://orcid.org/0000-0001-8755-4695)
- Chengcheng Yang (ORCID: https://orcid.org/0009-0005-1853-1234)
- Hong Ren (ORCID: https://orcid.org/0000-0003-1326-7719)
- Junke Fu (ORCID: https://orcid.org/0000-0002-3490-3086)
- Han Bai
- Jie Wu (ORCID: https://orcid.org/0000-0003-0991-4768)
Institutions
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1186/s12885-025-14220-x
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi Province